NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $13.82 +0.22 (+1.58%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$13.80 -0.01 (-0.07%) As of 08/8/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RDY alerts:Sign Up Key Stats Today's Range$13.62▼$13.8250-Day Range$13.36▼$16.1452-Week Range$12.26▼$16.89Volume1.11 million shsAverage Volume1.53 million shsMarket Capitalization$11.53 billionP/E Ratio20.93Dividend Yield0.51%Price Target$16.95Consensus RatingBuy Company Overview Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read More Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 51% of companies evaluated by MarketBeat, and ranked 576th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 2 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth2.50% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 2.50% in the coming year, from $0.80 to $0.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 20.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 20.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.03.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 5.52. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.46% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 11.43%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 10.61%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 8.54% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.46% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 11.43%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.15 News SentimentDr. Reddy's Laboratories has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dr. Reddy's Laboratories this week, compared to 5 articles on an average week.Search Interest2 people have searched for RDY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Stock News HeadlinesDr. Reddy's Laboratories (NYSE:RDY) vs. Aspen Pharmacare (OTCMKTS:APNHY) Head-To-Head Survey3 hours ago | americanbankingnews.comDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4, 2025 | seekingalpha.comAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Comparing Dr. Reddy's Laboratories (NYSE:RDY) and Acura Pharmaceuticals (OTCMKTS:ACUR)August 2, 2025 | americanbankingnews.comDr. Reddy’s Laboratories Releases Q1 2025 Earnings Call AudioJuly 25, 2025 | theglobeandmail.comDr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comDr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationJuly 23, 2025 | seekingalpha.comDr. Reddy's Q1FY26 Financial ResultsJuly 23, 2025 | businesswire.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $15.79 on January 1st, 2025. Since then, RDY shares have decreased by 12.5% and is now trading at $13.8150. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Ltd (NYSE:RDY) issued its earnings results on Wednesday, July, 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.02. The company earned $988.82 million during the quarter, compared to the consensus estimate of $88.27 billion. Dr. Reddy's Laboratories had a net margin of 16.99% and a trailing twelve-month return on equity of 17.25%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories's stock split before market open on Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly created shares were distributed to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Top institutional investors of Dr. Reddy's Laboratories include Robeco Institutional Asset Management B.V. (1.46%), Aikya Investment Management Ltd (0.76%), Acadian Asset Management LLC (0.25%) and Geode Capital Management LLC (0.16%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/23/2025Today8/09/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,811Year Founded1984Price Target and Rating Average Price Target for Dr. Reddy's Laboratories$16.95 High Price Target$17.00 Low Price Target$16.90 Potential Upside/Downside+22.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.66 Trailing P/E Ratio20.93 Forward P/E Ratio17.27 P/E Growth5.52Net Income$663 million Net Margins16.99% Pretax Margin22.77% Return on Equity17.25% Return on Assets11.63% Debt Debt-to-Equity Ratio0.01 Current Ratio1.89 Quick Ratio1.36 Sales & Book Value Annual Sales$3.81 billion Price / Sales3.03 Cash Flow$1.03 per share Price / Cash Flow13.36 Book Value$4.94 per share Price / Book2.80Miscellaneous Outstanding Shares834,900,000Free Float818,200,000Market Cap$11.53 billion OptionableOptionable Beta0.29 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:RDY) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.